Interacciones de los fármacos antirretrovirales

Medicina Clinica

Volumn 113, Issue 3, 1999, Pages 94-102

  Fuertes, Aurelio ^a   Otero, María José ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASTEMIZOLE; CISAPRIDE; CLARITHROMYCIN; DAPSONE; DELAVIRDINE; DIDANOSINE; FOSCARNET; GANCICLOVIR; INDINAVIR; ISONIAZID; LAMIVUDINE; METRONIDAZOLE; NELFINAVIR; NEVIRAPINE; PENTAMIDINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TERFENADINE; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; ZALCITABINE; ZIDOVUDINE;

COMPARATIVE STUDY; DRUG COMBINATION; DRUG INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW; TIME; BONE MARROW TOXICITY; CARDIOTOXICITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUCED DISEASE; DRUG METABOLISM; OPPORTUNISTIC INFECTION; PERIPHERAL NEUROPATHY; VIRUS INFECTION;

ANTI-HIV AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; TIME FACTORS;

EID: 0033606411     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Carpenter CCJ, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277: 1.962-1.969.
2. BHIVA Guidelines Coordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1.086-1.092.
3. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1.413-1.421.
4. Hammer SM, Squires KE, Hugues MD, Grimes JM, Demeter LM, Currier JS et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
5. Jankel CA, Speedie SM. Detecting drug interactions: a review of the literature. DICP Ann Pharmacother 1990; 24: 982-989.
6. Acosta EP, Page LM, Fletcher CV. Clinical pharmacokinetics of zidovudine. An update. Clin Pharmacokinet 1996; 251-262.
7. Perry CM, Balfour JA. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs 1996; 52: 925-962.
8. Shelton MJ, O'Donell AM, Morse GD. Zalcitabine. Ann Pharmacother 1993; 27: 480-489.
9. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171 (Supl 2): 99-112.
10. Lea AP, Faulds D. Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846-864.
11. Zerit (estavudina, d4T). Ficha técnica. Madrid: Bristol-Myers S.A., 1996.
12. Epivir (lamivudina). Ficha técnica. Madrid: Glaxo Wellcome, 1996.
13. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996; 52: 93-112.
14. Invirase (saquinavir). Ficha técnica. Madrid: Productos Roche, S.A., 1996.
15. Gallant J. Antiretrovirals: nucleoside analog and non-nucleoside reverse transcriptase inhibitors. Washington DC: 4th Conference on Retroviruses and Opportunistic Infections, 22-26 de enero de 1997.
16. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J, Tjia JF et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997; 11: 29-33.
17. Norvir (ritonavir). Ficha técnica. Madrid: Abbott Laboratories S.A., 1996.
18. Perry CM, Benfield P. Nelfinavir. Drugs 1997; 54: 81-87.
19. Crixiván (indinavir). Ficha técnica. Madrid: Merck Sharp & Dohme Ltd., 1997.
20. Viramune (nevirapine) tablets. Ridegfield CT: Boehringer Ingelheim Pharmaceutical Inc. FDA Summary Basis of Approval, 1996.
21. Drugdex® Editorial Staff. Drug evaluation monograph of delavirdine. Drugdex® Information System. Denver, Colorado: Micromedex Inc., 1997; 94.
22. Polis MA, Piscitelli SC, Vogel S, Witebsky FG, Conville PS, Petty B et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 1.709-1.714.
23. Vance E, Watson-Bitar M, Gustavson L, Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995; 39: 1.355-1.360.
24. Videx (didanosina, ddl). Ficha técnica. Madrid: Bristol-Myers S.A., 1993.
25. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drugs interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685-693.
26. Morse GD, Fischl MA, Shelton MJ, Borin MT, Driver MR, DeRemer M et al. Didanosine reduces atevirdine absorption in subjects with human immunodeficiency virus infection. Antimicrob Agents Chemother 1996; 40: 767-771.
27. Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M et al. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agentes Chemother 1997; 41: 169-174.
28. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996; 30: 385-401.
29. Welage LS, Carver PL, Revankar S, Pierson C, Kauffman CA. Alterations in gastric acidity in patients infected with human immunodeficiency virus. Clin Infect Dis 1995; 21: 1.431-1.438.
30. Smith PD, Quinn TC, Strober W, Janoff EN, Masur H. Gastrointestinal infections in AIDS. Ann Intern Med 1992; 116: 63-77.
31. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
32. Lertora JJL, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE et al. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 1994; 56: 272-278.
33. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169: 1.103-1.107.
34. Burlet RA, Carr JC, Drugdex® Editorial Staff. Drug evaluation monograph of indinavir. Drugdex® Information System. Denver, Colorado: Micromedex Inc., 1997; 94.
35. Lea AP, Faulds D. Ritonavir. Drugs 1996; 52: 541-546.
36. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
37. McDonald ChK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157: 951-959.
38. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145-153.
39. Viracept (nelfinavir mesylate). La Jolla, CA: Agouron Pharmaceuticals, Inc. FDA Summary Basis of Approval, 1997.
40. Drugdex® Editorial Staff. Drug evaluation monograph of ritonavir. Drugdex® Information System. Denver, Colorado: Micromedex Inc., 1997; 94.
41. McCrea J, Buss N, Stone J, Carides A, Dru J, Stewart F et al. Indinavir-saquinavir single dose pharmacokinetic study [resumen]. Washington, DC: 4th Conference on Retroviruses and Opportunistic Infections, 22-26 de junio de 1997.
42. Ferry JJ, Herman BD, Cox SR, Carlson GF, Calberry PA. Delavirdine (DLV) and indinavir (IDV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers. Washington, DC: 4th Conference on Retroviruses and Opportunistic Infections, 22-26 de junio de 1997.
43. Perry CM, Faulds D. Lamiduvine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs 1997; 53: 657-680.
44. Rana KZ, Dudley MN. Clinical pharmacokinetics of stavudine. Clin Pharmacokinet 1997; 33: 276-284.
45. Moore KHP, Yuen GJ, Raasch RH, Eron JJ, Martin D, Mydlow PK et al. Pharmacokinetics of lamivudine administered alone and with trimethorpim-sulfamethoxazole. Clin Pharmacol Ther 1996; 59: 550-558.
46. Abate M, Beaird S, Siepler J, Drugdex® Editorial Staff. Drug evaluation monograph of zalcitabine. Drugdex® Information System. Denver, Colorado: Micromedex Inc., 1997; 94.
47. Vistide (cidofovir). Monografia del producto. Kalamazoo MI. Pharmacia and Upjohn Company, 1997.
48. Ellis CJ, Leung D. Adverse drug reactions in patients with HIV infection. Adv Drug React Bull 1996; 178; 675-678.
49. Hochster H, Dieterich D, Bozzette S, Reichman RC, Connor JD, Liebes L et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: an AIDS clinical trials group study. Ann Intern Med 1990; 113: 111-117.
50. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J AIDS Hum Retrovirol 1995; 9: 153-161.
51. Cupler EJ, Dalakas MC. Exacerbation of peripheral neuropathy by lamivudine. Lancet 1995; 345: 995-996.
52. Cappell MD, Marks M. Acute pancreatitis in HIV-seropositive patients: a case control study of 44 patients. Am J Med 1995; 98: 243-248.
53. Anónimo. Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin. MMWR 1996; 45: 921-925.